How Does Lenvatinib — Starve a Tumour of Its Blood Supply?

No. Lenvatinib is a targeted therapy that blocks specific receptor signals. Chemotherapy works differently — it attacks all rapidly dividing cells, which is why it commonly causes hair loss and low blood counts. Lenvatinib's side effects reflect its specific targets: blood pressure changes, fatigue and effects on the palms and soles are common, but the mechanism is fundamentally different from cytotoxic chemotherapy. Both are systemic treatments, but they are not the same thing.

No — there is no physical sensation that tells you lenvatinib is active. Whether it is working is assessed through scans and blood tests at intervals your oncologist sets, not through how you feel day to day. Feeling unwell from side effects does not mean it is working, and feeling well does not mean it is not. The imaging and marker results are the only reliable answer to this question.

Lenvatinib works by maintaining a steady blood level that continuously occupies the receptors it targets. If you stop taking it, those receptors become available again and tumour signalling can resume. Chemotherapy is given in cycles because healthy cells need recovery time between doses. Lenvatinib's daily schedule is a direct consequence of how it does its job — it is pharmacology, not convenience.

Response is assessed through imaging — usually CT or PET-CT scans — at intervals your oncologist decides, typically in the first few months of treatment. For thyroid cancer, tumour markers in the blood such as thyroglobulin may also be tracked alongside imaging. NCCN and ESMO guidance supports regular imaging assessment rather than relying on symptoms alone. Your team will explain what they are looking for and what the results mean.

If lenvatinib stops controlling the cancer, your oncologist will discuss the next option. For thyroid and kidney cancers, alternative targeted agents are recognised by NCCN; for liver cancer, other systemic options exist depending on prior treatment. The honest answer is that it depends on your cancer type, what you have already had, and your current health. Asking about the next-line plan before you need it is entirely reasonable — it helps you understand your options without pressure.

Tell your oncology team about everything you are taking — including herbal preparations, supplements and ayurvedic medicines. Some plant-derived compounds affect the enzymes that process lenvatinib in the body, which can alter how much of the drug reaches your bloodstream. This is not a judgement of the practice; it is pharmacology that applies to many prescription medicines. Your treating team needs the complete picture to keep you safe.